

Figure S2 The maximum tumor size of consistent and inconsistent patients.




Figure S3 Plasmatic and tissue genetic information from patients after progression to first-line EGFR-TKI.

**Table S1** Comparison of the clinical characteristics of patients positive and negative for *TP53* mutation in ctDNA with consistent data from tumor samples

	<i>TP53</i> (+)	<i>TP53</i> (-)	P
Gender			0.633
Male	6	2	
Female	6	5	
Smoking			0.633
Yes	6	2	
No	6	5	
Family history			0.377
Yes	4	4	
No	8	3	
History of therapy			0.350
Yes	7	2	
No	5	5	
History of chemotherapy			0.245
Yes	4	0	
No	8	7	
History of TKI			1
Yes	3	2	
No	9	5	
History of anti-vascular therapy			1
Yes	1	0	
No	11	7	
History of radiotherapy			0.509
Yes	2	0	
No	10	7	
Treatment types			0.509
$\geq 2$	2	0	
$< 2$	10	7	
History of surgery			0.245
Yes	4	0	
No	8	7	
Inspection			0.206
Inspection of lung tissue	9	0	
Inspection of lymph node	3	6	
Other inspection sites	1	0	
Number of distant metastatic sites			0.656
$< 2$	5	2	
$\geq 2$	7	5	
Distant metastatic sites			
Pericardium			1
Yes	3	2	
No	9	5	
Brain			1
Yes	4	2	
No	15	3	
Lung			0.045
Yes	2	5	
No	10	2	
Liver			1
Yes	2	10	
No	1	6	
Bone			0.170
Yes	8	2	
No	4	5	
Adrenal gland			1
Yes	1	1	
No	11	6	
Pleura			1
Yes	4	8	
No	3	4	
Non-regional lymph node			1
Yes	1	0	
No	11	7	